<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552470</url>
  </required_header>
  <id_info>
    <org_study_id>C3421015</org_study_id>
    <nct_id>NCT04552470</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus</brief_title>
  <official_title>AN 8-WEEK PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TWICE DAILY PF-06882961 ADMINISTRATION IN JAPANESE ADULTS WITH TYPE 2 DIABETES MELLITUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double blind (sponsor open), parallel, placebo controlled,&#xD;
      twice daily oral dosing study of PF 06882961 in adult Japanese participants with T2DM&#xD;
      inadequately controlled on diet and exercise alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Actual">March 25, 2021</completion_date>
  <primary_completion_date type="Actual">February 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Treatment-Related Adverse Events</measure>
    <time_frame>Baseline up to 35 days after last dose (Day 91)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline up to 14 days after last dose (Day 70)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Baseline up to 14 days after last dose (Day 70)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG)</measure>
    <time_frame>Baseline up to 14 days after last dose (Day 70)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the Concentration-Time Curve</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours on Day 1; 0, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56;</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours on Day 1; 0, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56;</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours on Day 1; 0, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56;</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Terminal Half-Life</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36 and 48 hours on Day 56;</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be titrated up to 2 weeks to reach desired dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be titrated up to 4 weeks to reach desired dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be titrated up to 6 weeks to reach desired dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 matching placebo tablets taken twice a day (BID)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.</description>
    <arm_group_label>PF-06882961 120 mg</arm_group_label>
    <arm_group_label>PF-06882961 40 mg</arm_group_label>
    <arm_group_label>PF-06882961 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with T2DM who are treated with diet and exercise&#xD;
&#xD;
          -  HbA1c greater than or equal to 7% and less than or equal to 10.5%&#xD;
&#xD;
          -  Total body weight &gt;50 kg (110 lb) with BMI 22.5 to 45.4 kg/m^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption&#xD;
&#xD;
          -  Diagnosis of Type 1 diabetes&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina, arterial revascularization, stroke,&#xD;
             heart failure, or transient ischemic attack within 6 months of screening&#xD;
&#xD;
          -  Any malignancy not considered cured&#xD;
&#xD;
          -  Personal or family history of MTC or MEN2, or participants with suspected MTC&#xD;
&#xD;
          -  Acute pancreatitis or history of chronic pancreatitis&#xD;
&#xD;
          -  Symptomatic gallbladder disease&#xD;
&#xD;
          -  Known medical history of active proliferative retinopathy and/or macular edema&#xD;
&#xD;
          -  Known history of HIV, hepatitis B, hepatitis C or syphilis&#xD;
&#xD;
          -  Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or&#xD;
             equal to 100 mmHg (diastolic)&#xD;
&#xD;
          -  Clinically relevant ECG abnormalities&#xD;
&#xD;
          -  Positive urine drug test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P-one clinic, Keikokai medical corporation</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3421015</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

